Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer



Status:Active, not recruiting
Conditions:Ovarian Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:19 - Any
Updated:2/8/2019
Start Date:February 27, 2014

Use our guide to learn which trials are right for you!

A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer

This randomized phase II/III trial studies how well trametinib works and compares it to
standard treatment with either letrozole, tamoxifen citrate, paclitaxel, pegylated liposomal
doxorubicin hydrochloride, or topotecan hydrochloride in treating patients with low-grade
ovarian cancer or peritoneal cavity cancer that has come back, become worse, or spread to
other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. It is not yet known whether trametinib is more effective
than standard therapy in treating patients with ovarian or peritoneal cavity cancer.

PRIMARY OBJECTIVES:

I. To estimate the progression-free survival (PFS) hazard ratio of trametinib compared to
that of "commercially available therapies" consisting of one of five commercially available
agents in women with recurrent low-grade serous carcinoma of the ovary or peritoneum
previously treated with platinum-based chemotherapy.

SECONDARY OBJECTIVES:

I. To determine the nature, frequency and maximum degree of toxicity as assessed by Common
Terminology Criteria for Adverse Events (CTCAE) version (v)4 for each treatment arm.

II. To determine the quality of life, as assessed by the Functional Assessment of Cancer
Therapy-Ovarian (FACT-O).

III. To compare trametinib to the control arm with regard to patients' self-reported acute
(up to post-cycle 6) quality of life as measured by the FACT-O-Trial Outcome Index (TOI).

IV. To compare trametinib to the control arm with regard to patients' self-reported acute (up
to post-cycle 6) neurotoxicity as measured by the FACT-Gynecologic Oncology Group
(GOG)-Neurotoxicity (NTX).

V. To estimate the objective response rate (RR) of patients in each treatment arm.

TERTIARY OBJECTIVES:

I. To estimate the overall survival (OS) of patients in each treatment arm. II. To estimate
the tumor response rate in patients receiving trametinib after crossover from standard of
care.

III. To estimate the PFS in patients receiving trametinib after crossover from standard of
care.

IV. To compare trametinib to "endocrine standard therapy" (i.e., letrozole, tamoxifen) with
regard to patients' self-reported acute quality of life and neurotoxicity, as measured by the
FACT-O-TOI, and FACT-GOG-NTX, respectively.

V. To examine deoxyribonucleic acid (DNA) isolated from formalin-fixed, paraffin-embedded
sections of tissue from primary diagnosis, recurrence, and fine needle aspiration/core
biopsies with next generation sequencing mutational analyses of genes in the
mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3 kinase (PI3K)/v-akt murine
thymoma viral oncogene homolog 1 (AKT)/mammalian target of rapamycin (mTOR) pathways and to
explore their relationship with tumor response in patients treated with trametinib.
(Translational research objectives) VI. To examine protein levels of estrogen receptor (ER),
progesterone receptor (PR), phosphorylated (p)mitogen-activated protein kinase 1 (ERK), and
dual specificity phosphatase 6 (DUSP6) and explore their relationship with tumor response in
patients treated with trametinib. (Translational research objectives) VII. To identify
transcriptional signatures by ribonucleic acid sequencing (RNAseq) that will predict
mitogen-activated protein kinase kinase (MEK) addiction and sensitivity to trametinib.
(Translational research objectives) VIII. To conduct studies of specific genes in cell-free
DNA in plasma of patients and to explore their relationship with tumor response to
trametinib. (Translational research objectives) IX. To examine the pharmacokinetics of
trametinib. (Translational research objectives)

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM A: Patients receive clinician's choice of either letrozole orally (PO) once daily (QD) on
days 1-28, tamoxifen citrate PO twice daily (BID) on days 1-28, paclitaxel intravenously (IV)
over 1 hour on days 1, 8, and 15, pegylated liposomal doxorubicin hydrochloride (PLD) IV over
1 hour on day 1, or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses
repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients
developing progressive disease may cross over to Arm B.

ARM B: Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the
absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years,
every 6 months for 3 years, and then annually for 5 years.

Inclusion Criteria:

- Patients with the following tumors are included in the study:

- Patients initially diagnosed with low-grade serous ovarian or peritoneal
carcinoma that recur as low-grade serous carcinoma (invasive micropapillary
serous carcinoma or invasive grade I serous carcinomas as defined by GOG,
Federation of Obstetricians and Gynecologists [FIGO], World Health Organization
[WHO] or Silverberg)

- Patients initially diagnosed with serous borderline ovarian or peritoneal
carcinoma that recur as low-grade serous carcinoma (invasive micropapillary
serous carcinoma or invasive grade I serous carcinomas as defined by GOG, FIGO
WHO or Silverberg)

- At least 4 weeks must have elapsed since the patient underwent any major surgery (eg.
MAJOR: laparotomy, laparoscopy, thoracotomy, VATS [video assisted thorascopic
surgery]); there is no restriction on MINOR procedures: (eg. central venous catheter
placement, ureteral stent placement or exchange, tumor core or fine-needle aspirate
[FNA] biopsy)

- Patients must have documented low-grade serous carcinoma; confirmation must occur by
prospective pathology review prior to study entry; the prospective pathology review
can be done on tissue from the recurrent carcinoma or from original diagnostic
specimen

- All patients must have measurable disease as defined by Response Evaluation Criteria
in Solid Tumors (RECIST) 1.1; measurable disease is defined as at least one target
lesion that can be accurately measured in at least one dimension (longest diameter to
be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT),
magnetic resonance imaging (MRI), or caliper measurement by clinical exam; or >= 20 mm
when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured
by CT or MRI; all imaging studies must be performed within 28 days prior to
registration

- Prior therapy

- Patients must have recurred or progressed following at least one platinum-based
chemotherapy regimen

- Patients may have received an unlimited number of prior therapy regimens

- Patients may not have received all of the five choices in the "standard therapy"
arm

- Any hormonal therapy directed at the malignant tumor must be discontinued at
least one week prior to registration

- Any other prior therapy directed at the malignant tumor, including chemotherapy
and radiation therapy, must be discontinued at least 4 weeks prior to
registration; any investigational agent must be discontinued at least 28 days
prior to registration

- Women of childbearing potential (i.e. patients whose reproductive organs remain in
place and who have not passed menopause) and men must agree to use a highly effective
method of contraception (e.g. hormonal, intrauterine device or; abstinence*) prior to
study entry, during the study participation, and for six months after the last dose of
the drug; women of child-bearing potential must have a negative pregnancy test within
14 days prior to randomization, cannot be breast-feeding, and must agree to use a
highly effective form of contraception throughout the treatment period and for 6
months after the last dose of study treatment; should a woman become pregnant or
suspect she is pregnant while she or her partner is participating in this study, she
should inform her treating physician immediately; * abstinence is only acceptable when
this is in line with the preferred and usual lifestyle of the patient

- Patients must have the ability to understand and sign an approved informed consent and
authorization permitting release of personal health information

- Patients must have a GOG performance status of 0 or 1

- Able to swallow and retain orally-administered medication and does not have any
clinically significant gastrointestinal abnormalities that may alter absorption, such
as malabsorption syndrome, bowel obstruction, or major resection of the stomach or
bowel

- All prior treatment-related toxicities must be CTCAE v4 grade =< 1 (except alopecia)
at the time of randomization

- Patients must have a left ventricular ejection fraction >= lower limit of normal by
echocardiogram (ECHO) or multigated acquisition scan (MUGA)

- Serum creatinine =< 1.5 mg/dL OR calculated creatinine clearance (Cockcroft-Gault
formula) >= 50 mL/min OR 24-hour urine creatinine clearance >= 50 mL/min

- Bilirubin =< 1.5 times upper limit of normal

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times upper
limit of normal

- Albumin >= 2.5 g/dL

- Prothrombin time (PT) and activated partial thromboplastin time (APTT) =< 1.5 times
upper limit of normal

- Neutrophil count >= 1.5 x 10^9/L

- Platelet count >= 100 x 10^9/L

- Hemoglobin >= 9.0 g/dL

- If letrozole is selected as the control therapy, patients must be postmenopausal,
either following bilateral oophorectomy or at least 5 years after spontaneous
menopause; patients within 5 years of spontaneous menopause or who have had a
hysterectomy without bilateral oophorectomy must have postmenopausal luteinizing
hormone (LH) and follicle stimulating hormone (FSH) levels; patients on hormone
replacement therapy (HRT) must agree to withdrawal of hormone therapy before letrozole
is started

Exclusion Criteria:

- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to entering the study or those who have not
recovered from adverse events due to agents administered more than 4 weeks earlier

- Use of other investigational drugs within 28 days (or five half-lives, whichever is
shorter; with a minimum of 14 days from the last dose) preceding the first dose of
trametinib or standard of care agent

- If patients have had a potential index lesion radiated, it must have progressed post
radiation therapy to be used as a measurable eligibility lesion

- Patients may not have received prior MEK, v-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog (KRAS), or v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor
therapy

- Current use of a prohibited medication; the following medications or non-drug
therapies are prohibited:

- Patients may not be receiving any other anti-cancer or investigational agents

- The concurrent use of all herbal supplements is prohibited during the study
(including, but not limited to St. John's wort, kava, ephedra [ma huang], gingko
biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)

- Patients with known leptomeningeal or brain metastases or spinal cord compression
should be excluded from this clinical trial

- Patients with a bowel obstruction or any other gastrointestinal condition that might
affect absorption of the oral drug should be excluded; this would include patients
with inability to swallow and retain orally-administered medication, malabsorption
syndrome, or those with a major resection of the stomach or bowels

- Patients with a history of interstitial lung disease or pneumonitis

- Patients with a previous or current malignancy at other sites should be excluded, with
the exception of:

- Curatively treated local tumors such as carcinoma-in-situ of the cervix, basal or
squamous cell carcinoma of the skin

- Tumors for which no relapse has been observed within 5 years

- Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with
chronic or cleared HBV and HCV infection are eligible); patients with human
immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications

- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
chemically related to trametinib, or excipients, or to dimethyl sulfoxide (DMSO), or
to Cremophor EL (polyoxyethylated castor oil); please note, exclusion for Cremophor is
unnecessary unless paclitaxel is the only agent available and the patient randomizes
to the conventional therapy option

- Patients with a history or evidence of cardiovascular risk, including any of the
following:

- Left ventricular ejection fraction (LVEF) < lower limit of normal (LLN)

- Bazett's corrected QT (QTcB) >= 480 msec

- History or evidence of current clinically significant uncontrolled arrhythmias

- Exception: Subjects with controlled atrial fibrillation for > 30 days prior to
randomization are eligible

- History of (within 6 months prior to randomization) acute coronary syndromes
(including myocardial infarction and unstable angina), coronary angioplasty, or
stenting

- History or evidence of current >= class II congestive heart failure as defined by
New York Heart Association (NYHA)

- Treatment refractory hypertension defined as a blood pressure of systolic > 140
mmHg and/or diastolic > 90 mmHg which cannot be controlled by anti-hypertensive
therapy

- Patients with intra-cardiac defibrillators or permanent pacemakers

- Known cardiac metastases

- Patients with a history or current evidence/risk of retinal vein occlusion (RVO)

- Any serious and/or unstable pre-existing medical disorder (aside from malignancy
exception above), psychiatric disorder, or other conditions that could interfere with
subject's safety, obtaining informed consent or compliance to the study procedures

- Patients who require use of a concomitant medication that can prolong the QT interval

- Women of childbearing potential should be advised to avoid pregnancy and use effective
methods of contraception; if a female patient or a female partner of a patient becomes
pregnant while the patient receives trametinib, the potential hazard to the fetus
should be explained to the patient and partner (as applicable)
We found this trial at
498
sites
855 N. Westhaven Dr.
Oshkosh, Wisconsin 54904
920-303-8700
Principal Investigator: Elizabeth L. Dickson Michelson
Phone: 800-252-2990
Vince Lombardi Cancer Clinic - Oshkosh When the diagnosis is cancer, one of the most...
?
mi
from
Oshkosh, WI
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Teresa L. Rutledge
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: J. R. Liu
Phone: 734-712-3671
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Shashikant B. Lele
Phone: 877-275-7724
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: J. R. Liu
Phone: 734-712-3671
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
?
mi
from
Flint, MI
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Kelly J. Wilkinson
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Benjamin B. Bridges
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Richard G. Moore
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
(206) 667-5000
Principal Investigator: Heidi J. Gray
Phone: 800-422-6237
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Heidi J. Gray
Phone: 800-804-8824
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Benjamin B. Bridges
Phone: 206-215-3086
?
mi
from
Seattle, WA
Click here to add this to my saved trials
3900 W Avera Drive
Sioux Falls, South Dakota 57108
(605) 322-4700
Principal Investigator: Luis A. Rojas-Espaillat
Phone: 888-634-7268
Avera Cancer Institute Avera, the health ministry of the Benedictine and Presentation Sisters, is a...
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
808 North 39th Avenue
Yakima, Washington 98902
Principal Investigator: Paul G. Montgomery
Phone: 800-845-4624
?
mi
from
Yakima, WA
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Benjamin B. Bridges
Phone: 360-412-8958
?
mi
from
Aberdeen, WA
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
(215) 481–2000
Principal Investigator: Mark S. Shahin
Phone: 215-481-2402
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
?
mi
from
Abington, PA
Click here to add this to my saved trials
Albuquerque, New Mexico 87109
Principal Investigator: Teresa L. Rutledge
Phone: 505-272-0530
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Albuquerque, New Mexico 87106
Principal Investigator: Teresa L. Rutledge
Phone: 505-272-0530
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: J. R. Liu
Phone: 734-712-3671
?
mi
from
Allentown, PA
Click here to add this to my saved trials
170 North 1100 East
American Fork, Utah 84003
Principal Investigator: Xylina T. Gregg
Phone: 801-269-0304
?
mi
from
American Fork, UT
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
?
mi
from
Anaconda, MT
Click here to add this to my saved trials
Anacortes, Washington 98221
Principal Investigator: Paul G. Montgomery
Phone: 208-381-3376
?
mi
from
Anacortes, WA
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Paul G. Montgomery
Phone: 208-381-3376
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Benjamin B. Bridges
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Benjamin B. Bridges
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Benjamin B. Bridges
Phone: 412-339-5294
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Benjamin B. Bridges
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Benjamin B. Bridges
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Benjamin B. Bridges
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Benjamin B. Bridges
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: J. R. Liu
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
(404) 851-8000
Principal Investigator: Guilherme Henrique C. Cantuaria
Phone: 404-303-3355
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Auburn, California 95602
Principal Investigator: Stacy D. D'Andre
Phone: 415-209-2686
?
mi
from
Auburn, CA
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Stacy D. D'Andre
Phone: 415-209-2686
?
mi
from
Auburn, CA
Click here to add this to my saved trials
Auburn, Washington 98001
Principal Investigator: John A. Keech
Phone: 253-887-9333
?
mi
from
Auburn, WA
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Aurora, CO
Click here to add this to my saved trials
1501 S Potomac St
Aurora, Colorado 80012
(303) 695-2600
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Maria T. Grosse-Perdekamp
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
?
mi
from
Aurora, IL
Click here to add this to my saved trials
Bainbridge Island, Washington 98110
Principal Investigator: John A. Keech
Phone: 206-342-6954
?
mi
from
Bainbridge Island, WA
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Principal Investigator: J. R. Liu
Phone: 734-712-3671
?
mi
from
Baker City, OR
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Deborah K. Armstrong
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Principal Investigator: Mehmet S. Copur
Phone: 502-350-5700
?
mi
from
Bardstown, KY
Click here to add this to my saved trials
Baton Rouge, Louisiana 70815
Principal Investigator: Giles Fort
Phone: 225-216-1081
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
?
mi
from
Battle Creek, MI
Click here to add this to my saved trials
?
mi
from
Beachwood, OH
Click here to add this to my saved trials
Bellevue, Washington 98004
Principal Investigator: John A. Keech
Phone: 425-688-5407
?
mi
from
Bellevue, WA
Click here to add this to my saved trials
Bellevue, Washington 98005
Principal Investigator: Paul G. Montgomery
Phone: 800-845-4624
?
mi
from
Bellevue, WA
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Benjamin B. Bridges
Phone: 360-715-4133
?
mi
from
Bellingham, WA
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: John P. Kuebler
Phone: 614-488-2745
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
?
mi
from
Belpre, OH
Click here to add this to my saved trials
Bemidji, Minnesota 56601
?
mi
from
Bemidji, MN
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Benjamin B. Bridges
Phone: 541-647-7786
?
mi
from
Bend, OR
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Stacy D. D'Andre
Phone: 415-209-2686
?
mi
from
Berkeley, CA
Click here to add this to my saved trials
8901 Rockville Pike
Bethesda, Maryland 20889
(301) 295-4000
Principal Investigator: William J. Lowery
Phone: 301-319-2100
Walter Reed National Military Medical Center The Walter Reed National Military Medical Center is one...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Bethlehem, Pennsylvania 18015
Principal Investigator: Nicholas P. Taylor
Phone: 484-503-4510
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
?
mi
from
Billings, MT
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
406-237-7000
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
?
mi
from
Billings, MT
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
(701) 323-6000
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: J. R. Liu
Phone: 734-712-3671
?
mi
from
Boise, ID
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Benjamin B. Bridges
Phone: 412-339-5294
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
?
mi
from
Boise, ID
Click here to add this to my saved trials
Bolivar, Missouri 65613
?
mi
from
Bolivar, MO
Click here to add this to my saved trials
1100 Balsam Ave
Boulder, Colorado 80304
(303) 440-2273
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
?
mi
from
Boulder, CO
Click here to add this to my saved trials
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Boulder, CO
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 417-348-8032
?
mi
from
Branson, MO
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Principal Investigator: J. R. Liu
Phone: 734-712-3671
?
mi
from
Brighton, MI
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Principal Investigator: J. R. Liu
Phone: 734-712-3671
?
mi
from
Brighton, MI
Click here to add this to my saved trials
Bristol, England BS2
Principal Investigator: Axel Walther
Phone: 888-823-5923
?
mi
from
Bristol,
Click here to add this to my saved trials
Bryan, Texas 77802
Principal Investigator: Mehmet S. Copur
Phone: 979-774-0808
?
mi
from
Bryan, TX
Click here to add this to my saved trials
Burbank, California
Principal Investigator: Benjamin B. Bridges
Phone: 818-708-5550
?
mi
from
Burbank, CA
Click here to add this to my saved trials
Burien, Washington 98166
Principal Investigator: Mehmet S. Copur
Phone: 412-339-5294
?
mi
from
Burien, WA
Click here to add this to my saved trials
1501 Trousdale Drive
Burlingame, California 94010
Principal Investigator: Stacy D. D'Andre
Phone: 415-209-2686
?
mi
from
Burlingame, CA
Click here to add this to my saved trials
Burlington, Wisconsin 53105
Principal Investigator: Elizabeth L. Dickson Michelson
Phone: 800-252-2990
?
mi
from
Burlington, WI
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
406-723-2500
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
?
mi
from
Butte, MT
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Principal Investigator: J. R. Liu
Phone: 734-712-3671
?
mi
from
Caldwell, ID
Click here to add this to my saved trials
?
mi
from
Camden, NJ
Click here to add this to my saved trials
Cameron Park, California 95682
Principal Investigator: Stacy D. D'Andre
Phone: 415-209-2686
?
mi
from
Cameron Park, CA
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Principal Investigator: J. R. Liu
Phone: 734-712-3671
?
mi
from
Canton, MI
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Principal Investigator: J. R. Liu
Phone: 734-712-3671
?
mi
from
Canton, MI
Click here to add this to my saved trials
401 North Hooper Street
Caro, Michigan 48723
Principal Investigator: J. R. Liu
Phone: 734-712-3671
?
mi
from
Caro, MI
Click here to add this to my saved trials
Castro Valley, California 94546
Principal Investigator: Stacy D. D'Andre
Phone: 510-537-1234
?
mi
from
Castro Valley, CA
Click here to add this to my saved trials
1303 North Main Street
Cedar City, Utah 84721
(435) 868-5680
Principal Investigator: Xylina T. Gregg
Phone: 801-269-0304
Sandra L. Maxwell Cancer Center The Huntsman-Intermountain Cancer Center at Valley View Medical Center in...
?
mi
from
Cedar City, UT
Click here to add this to my saved trials
Centralia, Washington 98531
Principal Investigator: Benjamin B. Bridges
Phone: 360-412-8958
?
mi
from
Centralia, WA
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
Principal Investigator: Linda Van Le
Phone: 877-668-0683
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28204
Principal Investigator: John M. McDonald
Phone: 704-384-5369
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28207
Principal Investigator: John M. McDonald
Phone: 704-342-9577
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28262
Principal Investigator: John M. McDonald
Phone: 412-339-5294
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Chattanooga, Tennessee 37404
Principal Investigator: Mehmet S. Copur
Phone: 423-495-7730
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
14650 East Old US Highway 12
Chelsea, Michigan 48118
Principal Investigator: J. R. Liu
Phone: 734-712-3671
?
mi
from
Chelsea, MI
Click here to add this to my saved trials
775 South Main Street
Chelsea, Michigan 48118
Principal Investigator: J. R. Liu
Phone: 734-712-3671
?
mi
from
Chelsea, MI
Click here to add this to my saved trials
Cheyenne, Wyoming 82001
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Cheyenne, WY
Click here to add this to my saved trials
Chicago, Illinois 60625
Principal Investigator: Elyse A. Lambiase
Phone: 773-878-8200
?
mi
from
Chicago, IL
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
?
mi
from
Chicago, IL
Click here to add this to my saved trials
272 Hospital Rd
Chillicothe, Ohio 45601
740-779-7500
Principal Investigator: John P. Kuebler
Phone: 614-488-2745
Adena Regional Medical Center Since 1895, Adena Health System has remained focused on its commitment...
?
mi
from
Chillicothe, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45220
Principal Investigator: Mehmet S. Copur
Phone: 513-862-2230
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45242
Principal Investigator: Mehmet S. Copur
Phone: 513-862-2230
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45247
Principal Investigator: Mehmet S. Copur
Phone: 513-451-4033
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45255
Principal Investigator: Mehmet S. Copur
Phone: 513-451-4033
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45219
Principal Investigator: Eric L. Eisenhauer
Phone: 513-558-4553
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Clackamas, Oregon 97015
Principal Investigator: Benjamin B. Bridges
Phone: 503-215-2614
?
mi
from
Clackamas, OR
Click here to add this to my saved trials